This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2020 Jul 14;324(2):145-146.

doi: 10.1001/jama.2019.21793.

Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report

Lawrence O Gostin¹, Alastair J Wood², Patricia A Cuff³

Affiliations

Affiliations

¹ O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.
² Vanderbilt University, Nashville, Tennessee.
³ National Academies of Sciences, Engineering, and Medicine, Washington, DC.

PMID: 32134427
DOI: 10.1001/jama.2019.21793

Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report

Lawrence O Gostin et al. JAMA. 2020.

. 2020 Jul 14;324(2):145-146.

doi: 10.1001/jama.2019.21793.

Authors

Lawrence O Gostin¹, Alastair J Wood², Patricia A Cuff³

Affiliations

¹ O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.
² Vanderbilt University, Nashville, Tennessee.
³ National Academies of Sciences, Engineering, and Medicine, Washington, DC.

PMID: 32134427
DOI: 10.1001/jama.2019.21793

No abstract available

PubMed Disclaimer

Similar articles

Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.
Gaspar R. Gaspar R. Nanomedicine (Lond). 2007 Apr;2(2):143-7. doi: 10.2217/17435889.2.2.143. Nanomedicine (Lond). 2007. PMID: 17716116 Review. No abstract available.
The primacy of public health considerations in defining poor quality medicines.
Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ. Newton PN, et al. PLoS Med. 2011 Dec;8(12):e1001139. doi: 10.1371/journal.pmed.1001139. Epub 2011 Dec 6. PLoS Med. 2011. PMID: 22162953 Free PMC article.
Inspections: the international regulatory view.
Turner JL. Turner JL. PDA J Pharm Sci Technol. 1994 Jul-Aug;48(4):180-1. PDA J Pharm Sci Technol. 1994. PMID: 7804815 No abstract available.
Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
Griffiths E, Thorpe R, Wadhwa M, Sohn Y. Griffiths E, et al. Biologicals. 2011 Sep;39(5):249. doi: 10.1016/j.biologicals.2011.09.004. Epub 2011 Sep 16. Biologicals. 2011. PMID: 21925898 No abstract available.
Internationalization of regulatory requirements.
Juillet Y. Juillet Y. Fundam Clin Pharmacol. 2003 Feb;17(1):21-5. doi: 10.1046/j.1472-8206.2003.00118.x. Fundam Clin Pharmacol. 2003. PMID: 12588627 Review.

See all similar articles

Cited by

Good manufacturing practice in low- and middle-income countries: Challenges and solutions for compliance.
Chejor P, Dorji T, Dema N, Stafford A. Chejor P, et al. Public Health Chall. 2024 Jan 30;3(1):e158. doi: 10.1002/puh2.158. eCollection 2024 Mar. Public Health Chall. 2024. PMID: 40497059 Free PMC article.
Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem-Are We Ready for a Revolution?
Macdonald JC, Isom DC, Evans DD, Page KJ. Macdonald JC, et al. Front Med (Lausanne). 2021 May 21;8:660808. doi: 10.3389/fmed.2021.660808. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34109196 Free PMC article.
Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.
Durán CE, Cañás M, Urtasun M, Elseviers M, Vander Stichele R, Christiaens T. Durán CE, et al. PLoS One. 2021 Jul 13;16(7):e0254585. doi: 10.1371/journal.pone.0254585. eCollection 2021. PLoS One. 2021. PMID: 34255795 Free PMC article.
Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.
McAuslane N, Bujar M, Sithole T, Ngum N, Owusu-Asante M, Walker S. McAuslane N, et al. Pharmaceut Med. 2023 May;37(3):251-260. doi: 10.1007/s40290-023-00472-0. Epub 2023 Apr 19. Pharmaceut Med. 2023. PMID: 37074548 Free PMC article.
Strengthening regulatory systems for medicines in a changed world: where do we go from here?
O'Brien J, Lumsden R, Macdonald J. O'Brien J, et al. BMJ Glob Health. 2021 Jan;6(1):e004680. doi: 10.1136/bmjgh-2020-004680. BMJ Glob Health. 2021. PMID: 33495287 Free PMC article. No abstract available.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information